Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van KP, Victor A, Wein A: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002, 21: 167-178. 10.1002/nau.10052.
Article
PubMed
Google Scholar
Abrams P, Artibani W, Cardozo L, Dmochowski R, Van KP, Sand P: Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009, 28: 287-10.1002/nau.20737.
Article
PubMed
Google Scholar
Wein AJ, Rovner ES: Definition and epidemiology of overactive bladder. Urology. 2002, 60: 7-12.
Article
PubMed
Google Scholar
Ellsworth P: Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009, 5: 869-876.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ: Prevalence and burden of overactive bladder in the United States. World J Urol. 2003, 20: 327-336.
CAS
PubMed
Google Scholar
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006, 50: 1306-1314. 10.1016/j.eururo.2006.09.019.
Article
PubMed
Google Scholar
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001, 87: 760-766.
Article
CAS
PubMed
Google Scholar
Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Guan Z, Choo MS: Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009, 63: 560-567. 10.1111/j.1742-1241.2009.02035.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Castro D, Espuna M, Prieto M, Badia X: Prevalence of overactive bladder in Spain: a population-based study. Arch Esp Urol. 2005, 58: 131-138.
Article
PubMed
Google Scholar
Martinez AE, Ruiz Cerda JL, Gomez PL, Ramirez BM, Delgado OF, Rebollo P, Gonzalez-Segura AD, Arumi D: [Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study]. Actas Urol Esp. 2009, 33: 159-166.
Article
Google Scholar
Abrams P, Kelleher CJ, Kerr LA, Rogers RG: Overactive bladder significantly affects quality of life. Am J Manag Care. 2000, 6: S580-S590.
CAS
PubMed
Google Scholar
Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Lipton RB, Diokno AC: Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001, 57: 1044-1050. 10.1016/S0090-4295(01)00986-4.
Article
CAS
PubMed
Google Scholar
Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, Hunt TL: The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004, 7: 455-463. 10.1111/j.1524-4733.2004.74008.x.
Article
PubMed
Google Scholar
Patel B, Bavendam T, Badlani G: Use of antimuscarinics in the elderly. ScientificWorldJournal. 2009, 9: 459-465.
Article
CAS
PubMed
Google Scholar
Ouslander JG: Management of overactive bladder. N Engl J Med. 2004, 350: 786-799. 10.1056/NEJMra032662.
Article
CAS
PubMed
Google Scholar
D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R: Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008, 14: 291-301.
PubMed
Google Scholar
Swift SE, Siami P, Forero-Schwanhaeuser S: Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: an open-label, flexible-dosing, multicentre study. Clin Drug Investig. 2009, 29: 305-316. 10.2165/00044011-200929050-00003.
Article
CAS
PubMed
Google Scholar
Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J: Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011, 107: 1432-1440. 10.1111/j.1464-410X.2010.09640.x.
Article
CAS
PubMed
Google Scholar
Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010, 105: 58-66. 10.1111/j.1464-410X.2009.09086.x.
Article
CAS
PubMed
Google Scholar
Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P: Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract. 2008, 62: 1664-1674. 10.1111/j.1742-1241.2008.01893.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chapple CR, Van Kerrebroeck PE, Junemann KP, Wang JT, Brodsky M: Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008, 102: 1128-1132. 10.1111/j.1464-410X.2008.07907.x.
Article
CAS
PubMed
Google Scholar
Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z: Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008, 71: 839-843. 10.1016/j.urology.2007.12.017.
Article
PubMed
Google Scholar
Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, Siami P, Staskin DR: Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010, 75: 62-68. 10.1016/j.urology.2009.09.018.
Article
PubMed
Google Scholar
MacDiarmid SA: Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep. 2003, 4: 446-451. 10.1007/s11934-003-0025-z.
Article
PubMed
Google Scholar
Malone-Lee JG, Walsh JB, Maugourd MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001, 49: 700-705. 10.1046/j.1532-5415.2001.49144.x.
Article
CAS
PubMed
Google Scholar
Michel MC, Schneider T, Krege S, Goepel M: Does gender or age affect the efficacy and safety of tolterodine?. J Urol. 2002, 168: 1027-1031. 10.1016/S0022-5347(05)64567-3.
Article
CAS
PubMed
Google Scholar
Zinner NR, Mattiasson A, Stanton SL: Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002, 50: 799-807. 10.1046/j.1532-5415.2002.50203.x.
Article
PubMed
Google Scholar
Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A: Darifenacin treatment of patients > or = 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007, 23: 2347-2358. 10.1185/03007X226294.
Article
CAS
PubMed
Google Scholar
Kraus SR, Ruiz-Cerda JL, Martire D, Wang JT, Wagg AS: Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology. 2010, 76: 1350-1357. 10.1016/j.urology.2010.03.097.
Article
PubMed
Google Scholar
Stolley PD, Laporte J: The Public Health, the University, and Pharmacoepidemiology. Pharmacoepidemiology. Edited by: Strom BL. 2000, John Wiley & Sons, Third
Google Scholar
Gallagher RM: Naturalistic study designs in samples with refractory pain: advantages and limitations. Pain Med. 2004, 5: 143-145. 10.1111/j.1526-4637.2004.04036.x.
Article
PubMed
Google Scholar
Castro D, Miranda P, Sanchez-Ballester F, Arumi D, Lizarraga I, Ebel C: Assessment of reasons for overactive bladder treatment change. Actas Urol Esp. 2011, 35: 73-79. 10.1016/S2173-5786(11)70022-1.
Article
CAS
PubMed
Google Scholar
Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG: Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther. 2005, 22: 381-394. 10.1007/BF02850085.
Article
PubMed
Google Scholar
Colman S, Chapple C, Nitti V, Haag-Molkenteller C, Hastedt C, Massow U: Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology. 2008, 72: 803-807. 10.1016/j.urology.2008.05.033.
Article
CAS
PubMed
Google Scholar
Guy W: Clinical Global Impressions: In ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). 1976, Rockville, MDL: National Institute for Mental Health, 218-222.
Google Scholar
Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986, 24: 67-74. 10.1097/00005650-198601000-00007.
Article
CAS
PubMed
Google Scholar
Wagg A, Wyndaele JJ, Sieber P: Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006, 4: 14-24. 10.1016/j.amjopharm.2006.03.004.
Article
CAS
PubMed
Google Scholar
Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J: Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998, 63: 529-539. 10.1016/S0009-9236(98)90104-7.
Article
CAS
PubMed
Google Scholar
Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009, 47: 570-578.
Article
CAS
PubMed
Google Scholar
Wagg A, Khullar V, Marschall-Kehrel D, et al: Assessment of fesoterodine treatmetn in older people with overactive bladder: result of SOFIA, a double blind, placebo-controlled pan European trial. Eur Urol Supplement. 2011, 10: 276-277. [abstract]. e 2011
Article
Google Scholar
Chapple C, Van KP, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007, 52: 1204-1212. 10.1016/j.eururo.2007.07.009.
Article
CAS
PubMed
Google Scholar